July 7, 2021
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, June/July 2021

ECOG-ACRIN will hold its Fall 2021 Group Meeting as a face-to-face meeting for the first time in two years
July 7, 2021
Woman on smartphone

Mi Guía (My Guide) App for Hispanic/Latina Patients with Breast Cancer

Could a culturally-sensitive app help improve endocrine therapy medication adherence in Hispanic/Latina patients undergoing breast cancer treatment?
July 7, 2021
Barbara Burtness, MD

ECOG-ACRIN Creates Task Force on Advancement for Women

ECOG-ACRIN has established a Task Force on Advancement for Women under the leadership of Barbara Burtness, MD of Yale University
July 7, 2021
TMIST recruitment graph

Trial Updates: TMIST Enrollment Hits 50,000; NCI-MATCH News; Recent Research Results

Recent ECOG-ACRIN trial updates and results
July 7, 2021
Doctor patient consult in office

Now Enrolling: EA8192 for Upper Urinary Tract Cancer

This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
July 7, 2021
Colorectal cancer awareness ribbon

Now Enrolling: EA2201 for Rectal Adenocarcinoma

This phase II study will test the effect of nivolumab plus ipilimumab, with short-course radiation, for the neoadjuvant treatment of patients with low-lying, locally advanced MSI-H/dMMR rectal cancer
July 7, 2021
Older woman walking with doctor

Trial Spotlight: Efrat Dotan on the GIANT Study for Older Adults with Pancreatic Cancer

The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy
July 7, 2021
News in Brief

News in Brief, June 2021

May 28, 2021
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, May 2021

Virtual Spring 2021 Group Meeting generates record attendance; screening and genomic trials return to full activity
May 28, 2021
Doctor and patient reviewing test results

Now Enrolling: EA2192/APOLLO for Pancreatic Cancer

This phase II study, led by Dr. Kim Reiss Binder, is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
May 28, 2021
Evaluation Form

ECOG-ACRIN Recognizes 22 Member Networks and Programs for Outstanding Research Performance

In an annual evaluation, 22 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
May 28, 2021
Christine Lovly, MD, PhD headshot

ECOG-ACRIN Names Vanderbilt University’s Christine Lovly as Its 2021 Young Investigator of the Year

Dr. Lovly is the recipient of the 2021 ECOG-ACRIN Young Investigator Award, a highly prestigious recognition of research excellence